This article needs additional citations for verification .(May 2012) |
Type | Aktiengesellschaft |
---|---|
| |
ISIN | |
Industry | Pharmaceutical and Laboratory Equipment |
Founded | 1870 Göttingen, Germany |
Founder | Florenz Sartorius |
Headquarters | Göttingen, Germany |
Area served | Worldwide |
Key people |
|
Revenue | €3.45 billion (2021) [1] |
Number of employees | 13,832 (end 2021) [1] |
Website | sartorius |
Sartorius AG is an international pharmaceutical and laboratory equipment supplier, covering the segments of Bioprocess Solutions and Lab Products & Services.[ citation needed ]
In 2015, Sartorius Acquired cell line and process development Cellca. [2] By 2017, the subsidiary Sartorius Stedim Cellca was in operation, operating out of a rented facility in Laupheim, but by 2019 a new facility is slated to be occupied in the Eselsberg district of Ulm. [3]
2000
Sartorius took over B. Braun Biotech International (BBI) from B. Braun Melsungen AG. BBI, the world's leading manufacturer of fermenters (bioreactor) and cell culture systems at the time, was integrated into the Sartorius group as Sartorius Stedim Systems GmbH (formerly Sartorius BBI Systems GmbH ), a subsidiary of Sartorius Stedim Biotech GmbH.[ citation needed ]
Sartorius AG acquired the remaining shares in Viva Science and is now the sole owner.[ citation needed ]
2005
Sartorius acquires 100% of the shares of Omnimark Instrument Corporation, Arizona, United States (moisture analyzers).[ citation needed ]
2007
Sartorius merged its biotechnology division with the French biotech company Stedim S.A. The resulting Sartorius Stedim Biotech (SSB) is the world's leading technology provider for the biopharmaceutical industry. The new company is listed on the Paris stock exchange. [4] [5]
Sartorius took over the Toha Plast GmbH , which now operates under the name Sartorius Stedim Plastics .[ citation needed ]
2008
Through its subgroup, SSB Sartorius acquired the Swiss-based Wave Biotech AG, a leading provider of single-use bioreactors.[ citation needed ]
2011
Sartorius acquired the liquid handling business of the Finnish laboratory specialists Biohit. Thus, the Group expands its product portfolio in the field of laboratory instruments. [6] [ citation needed ]
2013
A new production building for the injection molding of plastic parts was opened in Göttingen. In the same year, the new Asia sales center of the Sartorius Group was inaugurated in Shanghai, from which all sales and marketing activities for China and for the entire Asia region are controlled. [7] [8]
2016
The company acquired two North American flow cytometry companies, IntelliCyt ($90 million) [9] and ViroCyt ($16 million).[ citation needed ]
In July, the company, through SSB, acquired kSep Systems, which specialized in preparative centrifugation for recombinant proteins, vaccines, and cell therapy products. [10]
In November, the SSB subdivision opened a new bioanalytical and biosafety testing facility in Boston. [11]
2017
The company acquired cell-based assay and instrumentation firm Essen BioScience, from private equity owner SFW Capital Partners, for $320 million. [12]
A co-development agreement between Sartorius' Cellca subsidiary and Synpromics began to test Synpromics' customized synthetic promoters on Cellca's CHO Expression Platform. [3]
Another co-development agreement was inked with Nova Biomedical to develop a system for large-scale testing of diverse cell culture conditions. [13]
2019
The company acquired the Israel cell culture media developer and manufacturer Biological Industries. [14]
2020
The company acquired selected assets of Danaher Corporation, including products for the research and development of cell therapies. [15]
2021
The company acquired the German cell culture media manufacturer Xell AG, [16] the German cell and gene therapy raw materials supplier CellGenix GmbH [17] and the German bioanalytic company ALS Automated Lab Solutions GmbH. [18]
BioOutsource is a subsidiary of Sartorius Stedim Biotech [25]
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.
Pharming, a portmanteau of "farming" and "pharmaceutical", refers to the use of genetic engineering to insert genes that code for useful pharmaceuticals into host animals or plants that would otherwise not express those genes, thus creating a genetically modified organism (GMO). Pharming is also known as molecular farming, molecular pharming or biopharming.
Danaher Corporation is an American globally diversified conglomerate founded by brothers Steven and Mitchell Rales in 1984. Headquartered in Washington, D.C., the company designs, manufactures, and markets medical, industrial, and commercial products and services. It has primarily grown by acquisitions, and historically has tried to maintain a very low public profile. Danaher was one of the first companies in North America to adopt the Kaizen principles to manufacturing, which is a lean manufacturing Japanese philosophy of continuous improvement and elimination of waste.
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).
This page provides an alphabetical list of articles and other pages about biotechnology.
Eppendorf, a company with its registered office in Germany, develops, produces and sells products and services for laboratories around the world.
A photobioreactor (PBR) refers to any cultivation system designed for growing photoautotrophic organisms using artificial light sources or solar light to facilitate photosynthesis. PBRs are typically used to cultivate microalgae, cyanobacteria, and some mosses. PBRs can be open systems, such as raceway ponds, which rely upon natural sources of light and carbon dioxide. Closed PBRs are flexible systems that can be controlled to the physiological requirements of the cultured organism, resulting in optimal growth rates and purity levels. PBRs are typically used for the cultivation of bioactive compounds for biofuels, pharmaceuticals, and other industrial uses.
Thermo Fisher Scientific Inc. is an American supplier of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).
Genedata is a world leader in bioinformatics, headquartered in Switzerland. The company offers enterprise software that supports large-scale, experimental processes in life science research. With an unwavering focus on automating data-rich, highly complex workflows in biopharmaceutical R&D Genedata has become the go-to platform for scientists and researchers around the globe. The Genedata Biopharma Platform is a suite of interoperable software designed to streamline every aspect of the biopharmaceutical development process, from early discovery to late-stage development and manufacturing. With Genedata's cutting-edge technology, researchers can accelerate their workflows, reduce costs, and make groundbreaking discoveries faster than ever before.
The virus counter is an instrument for rapid quantification of viruses in liquid samples. It is a specialized flow cytometer that uses high-sensitivity fluorescence detection to give a direct measurement of the concentration of virus particles in a fraction of the time required for traditional plaque assays.
A single-use bioreactor or disposable bioreactor is a bioreactor with a disposable bag instead of a culture vessel. Typically, this refers to a bioreactor in which the lining in contact with the cell culture will be plastic, and this lining is encased within a more permanent structure. Commercial single-use bioreactors have been available since the end of the 1990s and are now made by several well-known producers.
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
Geoffrey von Maltzahn is an American biological engineer and businessman in the biotechnology and life sciences industry who has founded a number of companies including Indigo Agriculture, Sana Biotechnology, Kaleido Biosciences, Seres Therapeutics, Axcella Health, Generate Biomedicines and Tessera Therapeutics. He has over 200 bioengineering and biotechnology patents and applications.
SOTIO Biotech is a Czech biotechnology company focused on clinical-stage research and development of innovative medicines for cancer with operations in Europe, North America, and Asia. The company has clinical programs which include a superagonist of the immuno-oncology target IL-15, a new generation of potent and stable antibody-drug conjugates (ADCs), proprietary technology designed to improve on the efficacy of CAR T therapies and a platform to streamline and enhance personalized cell therapies.
Uwe Marx is a German physician and biotechnologist, and one of the world’s leading researchers in the fields of organ-on-a-chip technology and antibody production.
Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.
WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development.
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, has been submitted for regulatory approval in 2023.